| EXAMINATION | - CHARLES J. RYAN ET AL, "Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy", NEW ENGLAND JOURNAL OF MEDICINE, (20130110), vol. 368, no. 2, doi:10.1056/NEJMoa1209096, ISSN 0028-4793, pages 138 - 148, XP055122065 | |
| OPPOSITION | - Anonymous, "Aragon Pharmaceuticals Announces Clinical Results from Ongoing Phase II Trial Confirming Robust Anti-Tumor Activity and Tolerability of ARN-509 in Three Different Patient Populations of Castration Resistant Prostate Cancer", Aragon Pharmaceuticals Press Release, (20121001), pages 1 - 3, XP055774120 | - |
| OPPOSITION | - Anonymous, "History changes story for NCT01650194 - A Study to Determine Safety and Tolerability of Enzalutamide (MDV3100) in Combination With Abiraterone Acetate in Bone Metastatic Castration-Resistant Prostate Cancer Patients", ClinicalTrials.gov, (20121129), pages 1 - 10, XP055774091 | - |
| OPPOSITION | - Anonymous, "History of changes for study: NCT01792687 Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of Ascending Doses of ARN 509 in Combination With Abiraterone Acetate", clinicaltrials.gov, (20130219), pages 1 - 10, XP055774522 | - |
| OPPOSITION | - Anonymous, "History of changes study for NCT01650194 - A Study to Determine Safety and Tolerability of Enzalutamide (MDV3100) in Combination With Abiraterone Acetate in Bone Metastatic Castration-Resistant Prostate Cancer Patients", Clinical Trial NCT01650194, (20121129), pages 1 - 5, URL: ClinicalTrials.gov, XP055774091 | - |
| OPPOSITION | - Anonymous, "History of changes study for NCT01650194 - A Study to Determine Safety and Tolerability of Enzalutamide (MDV3100) in Combination With Abiraterone Acetate in Bone Metastatic Castration-Resistant Prostate Cancer Patients", clinical trials.gov, (20121129), pages 1 - 5, URL: www.clinical trials.gov, XP055774091 | - |
| OPPOSITION | - Anonymous, "Poster Session Highlights of ASC02017", UroToday.com, (20170000), pages 1 - 2, XP055774078 | - |
| OPPOSITION | - Anonymous, "Xtandi® Highlights of prescribing information", Xtandi® label, (20120000), pages 1 - 16, XP055774057 | - |
| OPPOSITION | - Anonymous, "Xtandi® Highlights of prescribing information", Xtandi® label, (20120101), pages 1 - 16, Xtandi® label, (20210209), XP055774057 | - |
| OPPOSITION | - Anonymous, "Zytiga® Highlights of prescribing information", Zytiga® Label, (20110400), pages 1 - 22, XP055774038 | - |
| OPPOSITION | - Anonymous, "Zytiga® Highlights of prescribing information", Zytiga® Label, (20110401), pages 1 - 22, Zytiga®; Label, (20210209), XP055774038 | - |
| OPPOSITION | - Anonymous, "Zytostatika, andere antineoplastische mittel u. protektiva", Rote Liste®, (20110000), page 1841, XP055774411 | - |
| OPPOSITION | - A. OMLIN, "Compounds targeting androgen pathways", Targeted Therapies in Oncology, (20100000), pages 401 - 421, XP055774454 | - |
| OPPOSITION | - BRYCE et al., "Development and clinical utility of abiraterone acetate as an androgen synthesis inhibitor", Clin Pharmacol Ther, (20111130), vol. 91, no. 1, pages 101 - 108, XP055774377 | - |
| OPPOSITION | - Canadian label for abiraterone acetate | - |
| OPPOSITION | - Che-Kai Tsao , Matthew D Galsky, Alexander C Small, Tiffany Yee, William K Oh, "Targeting the androgen receptor signalling axis in castration-resistant prostate cancer (CRPC)", BJU International, (20120000), vol. 110, pages 1580 - 1588, XP055774431 | - |
| OPPOSITION | - Dana E. Rathkopf, Morris M.J. Et Al., "A phase I study of the androgen signaling inhibitor ARN-509 in patients with metastatic castration-resistant prostate cancer (mCRPC).", J. Clin. Oncol. 30, Suppl. Abstr. 4548, (20120530), J. Clin. Oncol. 30, Suppl. Abstr. 4548, URL: http://jco.ascopubs.org/gca?gca=ascomtg%3B30%2F15_suppl%2F4548&allch=citmgr&submit=Go, (20131209), XP055092165 | - |
| OPPOSITION | - DE BONO, "Interview with Johann de Bono for future oncology", Future Oncology, (20120000), vol. 8, no. 11, pages 1381 - 1382, XP055774383 | - |
| OPPOSITION | - D. RATHKOPF et al., "ARN-509 IN MEN WITH HIGH RISK NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (CRPC)", Annals of Oncology, (20120000), vol. 23, page ix317, XP055774478 | - |
| OPPOSITION | - Edwin M. Posadas, Kim N. Chi, Ronald De Wit, Maja J. De Jonge, Gerhardt Attard, Terence W. Friedlander, Margaret K. Yu, Peter Hellemans, Caly Chien, Charlene Connelly Abrams, Martha Gonzalez, Geralyn Carol Trudel, Vijay Chauhan, Juhui James Jiao, Fred Saad, "J Clin Oncology", J Clin Oncology Abstract 2017 ACRO Genitourinary Cancers Symposium, (20170200), vol. 35, no. 6, page 173, XP055774070 | - |
| OPPOSITION | - E.S. ANTONARAKIS, "Abiraterone acetate for prostate cancer: a new era of hormonal therapies", Asian J. Androl., (20110000), vol. 13, pages 663 - 664, XP055774444 | - |
| OPPOSITION | - JANSSEN, "ZYTIGA® (abiraterone acetate) tablets - HIGHLIGHTS OF PRESCRIBING INFORMATION", Zytiga Leaflet (SmPC), (20121200), pages 1 - 22, XP055774400 | - |
| OPPOSITION | - John Caroll, "Aragon Pharmaceuticals -2012 Fierce 15", Fierce Biotech, (20120919), pages 1 - 3, XP055774124 | - |
| OPPOSITION | - Kevin D Courtney 1, Mary-Ellen Taplin, "The evolving paradigm of second-line hormonal therapy options for castration-resistant prostate cancer", Curr. Opin. Oncol., (20120000), vol. 24, pages 272 - 277, XP055774446 | - |
| OPPOSITION | - POSADAS E et al., "Abiraterone in Metastatic prostate cancer without previous chemotherapy", Poster from ASCO Genitourinary Cancers Symposium, (20170200), pages 138 - 148, XP055773942 | - |
| OPPOSITION | - Rathkopf Dana E (correspondence); Danila Daniel Costin; Morris Michael J; Slovin Susan F; Steinbrecher Jill Elise; Arauz Gabrielle; Rix Peter J; Maneval Edna Chow; Chen Isan; Fox Josef J; Fleisher Martin; Larson Steven M; Scher Howard I, "A phase I/II safety and pharmacokinetic (PK) study of ARN-509 in patients with metastatic castration-resistant prostrate cancer clinical trials consortium study", J. Clin. Oncol., (20120210), vol. 30, no. 5, pages 43 - 43, XP008166218 | - |
| OPPOSITION | - Rathkopf, Dana E. (correspondence); Danila, Daniel Costin; Morris, Michael J.; Slovin, Susan F.; Steinbrecher, Jill Elise; Arauz, Gabrielle; Rix, Peter J.; Maneval, Edna Chow; Chen, Isan; Fox, Josef J.; Fleisher, Martin; Larson, Steven M.; Scher, Howard I., "Phase I/II safety and pharmacokinetic (PK) study of ARN - 509 in patients with metastatic castration - resistant prostate cancer (mCRPC): Phase I results of a Prostate Cancer Clinical Trials Consortium study.", Journal of Clinical Oncology, American Society of Clinical Oncology, US, US , (20120210), vol. 30, no. 5, SUPPL. 1, ISSN 0732-183X, page Abstr. 43, XP008166218 | - |
| OPPOSITION | - Rathkopf Dana E (correspondence); Shore Neal; Antonarakis Emmanuel S; Berry William R; Alumkal Joshi J; Tutrone Ronald; Saleh Mansoor N; Redfern Charles H; Hauke Ralph J; Liu Glenn; Steinbrecher Jill Elise; Danila Daniel Costin; Curley Tracy; Arauz Gabrielle; Rix Peter J; Maneval Edna Chow; Chen Isan; Scher Howard I, "A phase II study of the androgen signaling inhibitor ARN - 509 in patients with castration - resistant prostate cancer (CRPC)", JOURNAL OF CLINICAL ONCOLOGY ; 2012 ANNUAL MEETING OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY, US ; CHICAGO, IL , UNITED STATES, (20120520), vol. 30, no. 15, pages 1 - 4, XP008166219 | - |
| OPPOSITION | - Rathkopf, Dana E. (correspondence); Shore, Neal; Antonarakis, Emmanuel S.; Berry, William R.; Alumkal, Joshi J.; Tutrone, Ronald; Saleh, Mansoor N.; Redfern, Charles H.; Hauke, Ralph J.; Liu, Glenn; Steinbrecher, Jill Elise; Danila, Daniel Costin; Curley, Tracy; Arauz, Gabrielle; Rix, Peter J.; Maneval, Edna Chow; Chen, Isan; Scher, Howard I., "A phase II study of the androgen signaling inhibitor ARN - 509 in patients with castration - resistant prostate cancer (CRPC).", Journal of Clinical Oncology, American Society of Clinical Oncology, US, US , (20120520), vol. 30, no. 15, SUPPL. 1, ISSN 0732-183X, page Abstr. TPS4697, XP008166219 | - |
| OPPOSITION | - Rathkopf, D.E. (correspondence); Danila, D.C.; Slovin, S.F.; Morris, M.J.; Steinbrecher, J.E.; Chen, Y.; Fleisher, M.; Larson, S.M.; Sawyers, C.L.; Scher, H.I. Rathkopf, D.E. (correspondence); Danila, D.C.; Slovin, S.F.; Morris, M.J.; Steinbrecher, J.E.; Chen, Y.; Fleisher, M.; Larson, S.M.; Sawyers, C.L.; Scher, H.I., "A first-in-human, open-label, phase I/II safety, pharmacokinetic, and proof-of-concept study of ARN - 509 in patients with progressive advanced castration - resistant prostate cancer ( CRPC ).", Journal of Clinical Oncology, American Society of Clinical Oncology, US, US , (20110520), vol. 29, no. 15, SUPPL. 1., ISSN 0732-183X, page TPS190, XP008166220 | - |
| OPPOSITION | - RATHKOPF D E et al., "A first-in-human, open-label, phase l/ll safety, pharmacokinetic, and proof-of-concept study of ARN - 509 in patients with progressive advanced castration - resistant prostate cancer ( CRPC", JOURNAL OF CLINICAL ONCOLOGY; ASCO ANNUAL MEETING 2011, US ; CHICAGO, IL , UNITED STATES, (20110520), vol. 29, no. 15, ISSN 0732-183X, page TPS190, XP008166220 | - |
| OPPOSITION | - Sawyers Charles L., "The 2011 Gordon Wilson Lecture: overcoming resistance to targeted cancer drugs", Trans Am Clin Climatol Assoc, (20120101), vol. 123, pages 114 - 125, XP055976298 | - |
| OPPOSITION | - Marianne D Sadar, "Advances in small molecule inhibitors of androgen receptor for the treatment of advanced prostate cancer", World Journal of Urology, (20120000), vol. 30, no. 3, pages 311 - 318, XP035062113 | |
| OPPOSITION | - Niraula Saroj; Chi Kim; Joshua Anthony Michael, "Beyond Castration—Defining Future Directions in the Hormonal Treatment of Prostate Cancer", Hormones and Cancer, (20120000), vol. 3, no. 3, pages 3 - 13, XP037320404 | |
| OPPOSITION | - de Bono J S, Logothetis C J, Molina A, Fizazi K, North S, Chu L, Chi K N, Jones R J, Goodman O B, Saad F, Staffurth J N, Mainwaring P, Harland S, Flaig T W, Hutson T E, Cheng T, Patterson H, Hainsworth J D, Ryan C J, Sternberg C N, Ellard S L, Fléchon A, Saleh M, Scholz M, Efstathiou E, Zivi A, Bianchini D, Loriot Y, Chieffo N, Kheoh T, Haqq C M, Scher H I; COU-AA-301 Investigators., "Abiraterone and increased survival in metastatic prostate cancer.", New England Journal of Medicine, The - NEJM, Massachusetts Medical Society, US, US , (20110526), vol. 364, no. 21, doi:10.1056/NEJMoa1014618, ISSN 1533-4406, pages 1995 - 2005, XP002725563 | |
| OPPOSITION | - CHARLES J. RYAN et al., "Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy", NEW ENGLAND JOURNAL OF MEDICINE, (20130110), vol. 368, no. 2, doi:10.1056/NEJMoa1209096, ISSN 0028-4793, pages 138 - 148, XP055122065 | |
| OPPOSITION | - Charles J. Ryan, Matthew R. Smith, Johann S. De Bono, Arturo Molina, Christopher J. Logothetis, Paul De Souza, Karim Fizazi, Paul Mainwaring, Josep M. Piulats, Siobhan Ng, Joan Carles, Peter F.A. Mulders, Ethan Basch, Eric J. Small, Fred Saad, Dirk Schrijvers, Hendrik Van Poppel, Som D. Mukherjee, Henrik Suttmann, Winald R. Gerritsen, Thomas W. Flaig, Daniel J. George, Evan Y. Yu, Eleni Efstathiou, Allan Pantuck, Eric Winquist, Celestia S. Higano, Mary-Ellen Taplin, Youn Park, Thian Kheoh, Thomas Griffin, Howard I. Scher, Dana E. Rathkopf, "Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy", New England Journal of Medicine, New England Journal of Medicine, (20130110), vol. 368, no. 2, doi:10.1056/NEJMoa1209096, ISSN 00284793, pages 138 - 148, XP055122065 | |
| OPPOSITION | - mith M R; Antonarakis E S; Ryan C J; Berry W; Shore N D; Liu G; Alumkal J; Higano C; Chow-Maneval E; Rathkopf D, "ARN-509 IN MEN WITH HIGH RISK NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER", Annals of Oncology, (20120000), vol. 23, no. 9, page ix303, XP008166216 | |
| OPPOSITION | - M.R. Smith, E.S. Antonarakis, C.J. Ryan, W. Berry, N.D. Shore, G. Liu, J. Alumkal, C. Higano, E. Chow-Maneval, D. Rathkopf, "ARN-509 IN MEN WITH HIGH RISK NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER", Annals of Oncology, Kluwer Dordrecht, NL, NL , (20120901), vol. 23, no. Suppl. 9, doi:10.1093/annonc/mds400, ISSN 0923-7534, page 303, XP008166216 | |
| OPPOSITION | - Smith M R; Antonarakis E S; Ryan C J; Berry W; Shore N D; Liu G; Alumkal J; Higano C; Chow-Maneval E; Rathkopf D, "ARN-509 IN MEN WITH HIGH RISK NON- METASTATIC CASTRATION-RESISTANT PROSTATE CANCER", ANNALS OF ONCOLOGY; ABSTRACT BOOK OF THE 37 TH ESMO CONGRESS, KLUWER, DORDRECHT, NL ; VIENNA, AUSTRIA, (20120901), vol. 23, no. 9, page 303, XP008166216 | |
| OPPOSITION | - Feng H C; Tsao S W; Ngan H Y S; Xue W C; Kwan H-S; Siu M K Y; Liao X-Y; Wong E; Cheung A N Y, "Overexpression of prostate stem cell antigen is associated with gestational trophoblastic neoplasia", Curr. Opin. Urol., (20120000), vol. 22, pages 167 - 174, XP009122538 | |
| OPPOSITION | - Clegg N J; Wongvipat J; Joseph J D; Tran C; Ouk S; Dilhas A; Chen Y; Grillot K; Bischoff E D; Cai L; Aparicio A; Dorow S; Arora V; Shao G; Qian J; Zhao H; Yang G; Cao C; Sensintaffar J; Wasielewska T; Herbert M R; Bonnefous C; Darimont B; Scher H I; Smith-Jones P; Klang M; Smith N D; De Stanchina E; Wu N; Ouerfelli O; Rix P J; Heyman R A; Jung M E; Sawyers C L; Hager J H, "ARN-509: a novel antiandrogen for prostate cancer treatment", Cancer Res., (20120000), vol. 72, no. 6, pages 1494 - 1503, XP002756285 | |
| OPPOSITION | - Clegg N J; Wongvipat J; Joseph J D; Tran C; Ouk S; Dilhas A; Chen Y; Grillot K; Bischoff E D; Cai L; Aparicio A; Dorow S; Arora V; Shao G; Qian J; Zhao H; Yang G; Cao C; Sensintaffar J; Wasielewska T; Herbert M R; Bonnefous C; Darimont B; Scher H I; Smith-Jones P; Klang M; Smith N D; De Stanchina E; Wu N; Ouerfelli O; Rix P J; Heyman R A; Jung M E; Sawyers C L; Hager J H, "ARN-509: a novel antiandrogen for prostate cancer treatment", Cancer Res, (20120120), vol. 72, no. 6, pages 1494 - 1503, XP002756285 | |
| OPPOSITION | - Clegg N J; Wongvipat J; Joseph J D; Tran C; Ouk S; Dilhas A; Chen Y; Grillot K; Bischoff E D; Cai L; Aparicio A; Dorow S; Arora V; Shao G; Qian J; Zhao H; Yang G; Cao C; Sensintaffar J; Wasielewska T; Herbert M R; Bonnefous C; Darimont B; Scher H I; Smith-Jones P; Klang M; Smith N D; De Stanchina E; Wu N; Ouerfelli O; Rix P J; Heyman R A; Jung M E; Sawyers C L; Hager J H, "ARN-509: a novel antiandrogen for prostate cancer treatment", CANCER RES, (20120315), vol. 72, no. 6, pages 1494 - 1503, XP002756285 | |
| OPPOSITION | - Clegg N J, Wongvipat J, Joseph J D, Tran C, Ouk S, Dilhas A, Chen Y, Grillot K, Bischoff E D, Cai L, Aparicio A, Dorow S, Arora V, Shao G, Qian J, Zhao H, Yang G, Cao C, Sensintaffar J, Wasielewska T, Herbert M R, Bonnefous C, Darimont B, Scher H I, Smith-Jones P, Klang M, Smith N D, De Stanchina E, Wu N, Ouerfelli O, Rix P J, Heyman R A, Jung M E, Sawyers C L, Hager J H, "ARN-509: a novel antiandrogen for prostate cancer treatment.", Cancer research, American Association for Cancer Research, 2019 San Antonio Breast Cancer Symposium, San Antonio, Texas, 2019 San Antonio Breast Cancer Symposium, San Antonio, Texas , (20120315), vol. 72, no. 6, doi:10.1158/0008-5472.CAN-11-3948, ISSN 0008-5472, pages 1494 - 1503, XP002756285 | |
| OPPOSITION | - J. RICHARDS et al., "Interactions of Abiraterone, Eplerenone, and Prednisolone with Wild-type and Mutant Androgen Receptor: A Rationale for Increasing Abiraterone Exposure or Combining with MDV3100", Cancer Res, (20120000), vol. 72, no. 9, pages 2176 - 2182, XP055654799 | |
| OPPOSITION | - Richards J; Lim A C; Hay C W; Taylor A E; Wingate A; Nowakowska K; Pezaro C; Carreira S; Goodall J; Arlt W; Mcewan I J; De Bono J S; Attard G, "Interactions of Abiraterone, Eplerenone, and Prednisolone with Wild-type and Mutant Androgen Receptor: A Rationale for Increasing Abiraterone Exposure or Combining with MDV3100", Cancer Res, (20120312), vol. 72, no. 9, pages 2176 - 2182, XP055654799 | |
| OPPOSITION | - G. ATTARD et al., "New Strategies in Metastatic Prostate Cancer: Targeting the Androgen Receptor Signaling Pathway", Clinical Cancer Research, (20110000), vol. 17, no. 7, pages 1649 - 1657, XP055139706 | |
| OPPOSITION | - Mostaghel E A, Marck B T, Plymate S R, Vessella R L, Balk S, Matsumoto A M, Nelson P S, Montgomery R B, "Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants.", Clinical Cancer Research, Association for Cancer Research, US, US, (20110915), vol. 17, no. 18, doi:10.1158/1078-0432.CCR-11-0728, ISSN 1078-0432, pages 5913 - 5925, XP002712865 | |
| OPPOSITION | - Michael T Schweizer; Emmanuel S Antonarakis, "Abiraterone and other novel androgen-directed strategies for the treatment of prostate cancer: a new era of hormonal therapies is born", Therapeutic Advances in Urology, vol. 4, no. 4, pages 167 - 178, XP055491443 | |
| OPPOSITION | - M.T. SCHWEITZER et al., "Abiraterone and other novel androgen-directed strategies for the treatment of prostate cancer: a new era of hormonal therapies is born", Therapeutic Advances in Urology, (20120000), vol. 4, no. 4, pages 167 - 178, XP055491443 | |
| OPPOSITION | - E. Efstathiou, M. Titus, D. Tsavachidou, V. Tzelepi, S. Wen, A. Hoang, A. Molina, N. Chieffo, L. A. Smith, M. Karlou, P. Troncoso, C. J. Logothetis, "Effects of Abiraterone Acetate on Androgen Signaling in Castrate-Resistant Prostate Cancer in Bone", Journal of Clinical Oncology, (20120220), vol. 30, no. 6, doi:10.1200/JCO.2010.33.7675, ISSN 0732183X, pages 637 - 643, XP055139375 | |
| OPPOSITION | - Ryan Charles J; Tindall Donald J, "Androgen receptor rediscovered: the new biology and targeting the androgen receptor therapeutically", J Clin Oncology, (20110000), vol. 29, no. 27, pages 3651 - 3658, XP009160280 | |
| OPPOSITION | - Ryan Charles J; Tindall Donald J, "Androgen receptor rediscovered: the new biology and targeting the androgen receptor therapeutically", Journal of Clinical Oncology, (20110920), vol. 29, no. 27, doi:10.1200/JCO.2011.35.2005, pages 3651 - 3658, XP009160280 | |
| OPPOSITION | - Leibowitz-amit R; Joshua A, "Targeting the androgen receptor in the management of castrationresistant prostate cancer: rationale, progress, and future directions", Current Oncology, (20121203), vol. 19, pages S22 - S31, XP055312138 | |
